Business Context and Reporting Period
Filing: Form 8-K dated December 12, 2022, filed by Priveterra Acquisition Corp., a special purpose acquisition company. The filing announces a definitive business combination agreement with AEON Biopharma, Inc. (“AEON”), a biopharmaceutical company.
Priveterra Merger Sub, Inc. will merge with and into AEON, with AEON surviving as a wholly owned subsidiary. At closing, Priveterra will change its name to AEON Biopharma, Inc. The transaction had been approved by the boards of directors of both parties but had not closed as of the filing date.
Transaction Terms and Key Financial Items
- AEON equity holders will receive Priveterra Class A common stock based on an implied AEON equity value of $165 million.
- 809,000 shares otherwise issuable as merger consideration will be held back to satisfy the exercise of certain AEON convertible notes at maturity.
- AEON stockholders may receive up to 16 million additional earnout shares upon achievement of specified clinical and regulatory milestones.
- Earnout milestones relate to commencement of a Phase 3 migraine study and FDA acceptance for review of biologics license applications for cervical dystonia, episodic migraine, and chronic migraine.
- Outstanding AEON equity options will be assumed by Priveterra and adjusted for the transaction.
- AEON is expected to pursue interim financing of up to $20 million from AEON stockholders or other sources.
- If the transaction has not closed by March 1, 2023, AEON is expected to obtain a $4 million bridge loan by March 7, 2023, subject to the agreement’s terms.
- If specified conditions remain unmet by the applicable Priveterra bridge loan date, the Sponsor or another financing source is expected to provide an additional $8 million bridge loan, provided the required AEON interim financing arrangements are in place.
- AEON’s closing condition includes available closing cash of at least $45 million, after applicable redemptions, transaction expenses, and certain interim financing commitments.
- The combined company must have at least $5,000,001 of net tangible assets at closing and satisfy Nasdaq listing requirements.
The filing does not provide revenue, profit, operating cash flow, margins, cash balances, total debt, or other historical financial statements for AEON or Priveterra.
Material Changes Versus the Prior Comparable Period
The filing is a transaction announcement rather than a periodic earnings report. It does not present comparative financial results or quantify changes from a prior period. The principal development is Priveterra’s entry into the definitive agreement to acquire AEON and the related financing, support, earnout, and governance arrangements.
Guidance, Outlook, Risks, and Unusual Items
- Completion remains subject to stockholder approvals, effectiveness of an S-4 registration statement, Nasdaq approval, antitrust waiting-period requirements, minimum cash and net tangible asset conditions, and other customary closing conditions.
- The agreement may be terminated in specified circumstances, including uncured breaches, failure to obtain required approvals, regulatory prohibition, or failure to satisfy closing conditions. The stated termination date is March 1, 2023, subject to extensions described in the agreement.
- Priveterra’s Sponsor agreed to support the transaction by voting its Class B shares and 5.28 million private placement warrants in favor of the transaction and related proposals.
- Approximately 50% of the Sponsor’s shares, or 3.45 million shares, will be subject to milestone-based vesting and forfeiture provisions following closing.
- AEON supporting stockholders agreed to vote in favor of the transaction and accepted transfer restrictions generally lasting until the earlier of one year after closing or certain qualifying transactions, with market-price-based early release provisions.
- AEON noteholders agreed to convert their existing convertible notes into AEON common stock immediately before closing and waived specified cash, liquidation, preemptive, and earnout rights.
- Key risks include failure to close the merger, stockholder redemptions or insufficient financing, regulatory and clinical-trial delays, failure to obtain FDA approvals, competition, intellectual-property risks, dependence on key personnel, COVID-19 effects, and the ability to commercialize AEON’s product candidates.
- The filing contains forward-looking statements regarding clinical development, regulatory milestones, financing, transaction benefits, markets, expenses, and future profitability. No formal revenue or earnings guidance is provided.
Important Facts for Investors to Verify
- Review the definitive S-4 registration statement and proxy statement for the final transaction structure, share counts, dilution, redemption assumptions, and pro forma ownership.
- Verify whether the required $45 million available closing cash condition and $5,000,001 net tangible asset condition are satisfied.
- Confirm the terms, funding, and status of the proposed $20 million interim financing and potential $4 million and $8 million bridge loans.
- Assess AEON’s clinical pipeline, trial results, regulatory status, FDA filing plans, and the likelihood and timing of the earnout milestones.
- Review AEON’s historical financial statements, cash burn, debt obligations, convertible-note terms, liquidity needs, and going-concern disclosures when filed.
- Evaluate dilution from merger consideration, earnout shares, assumed options, converted notes, warrants, Sponsor shares, and potential redemptions.
- Monitor required stockholder approvals, SEC effectiveness of the S-4, Nasdaq listing approval, antitrust clearance, closing timing, and any amendments or termination notices.